Please wait while your account is being registered at Beautetrade.com Loading Spinner

  1. Home
  2. Skin Care
  3. Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
  • Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
  • Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
  • Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
  • Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss
  • Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss

Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss

FOB Price: $180- $280
|
1 box (Min. Order)
  • MOQ.: 1 box
  • Packaging: 50pcs/box
  • Port shenzhen
  • Lead Time 3-5day
Quick Details
140
Product Details

What is Ozempic®?Ozempic®  injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease. 

 

Price Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight LossPrice Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight LossPrice Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight LossPrice Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight LossPrice Ozempic 3ml 1.5ml Pen Wegovys Victoza Fat Dissolve for Weight Loss

The FDA granted approval for  for the treatment of chronic weight management, combined with a reduced-calorie diet and physical activity, in December 2014.The drug is designed for adults with obesity (body mass index (BMI) >30) or overweight (BMI >27) and also affected with one obesity-related condition such as type 2 diabetes, cardiovascular disease, hypertension or high cholesterol.In April 2020, a supplemental indication for the drug received approval from the FDA for chronic weight management in obese patients aged 12 years and older.In March 2021, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use recommended the use of the drug for treating obesity in adolescents aged 12-17 years.

More Products From this Supplier